By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BioCon Limited 

20th KM Hosur Road

Electronics City  Bangalore  560 100  India
Phone: 90-80-2808-2808 Fax: 91-80-2852-3423


SEARCH JOBS


Industry
Biotechnology






Company News
FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval Of Mylan (MYL) And BioCon (BIOCON.NS)'s Proposed Biosimilar Trastuzumab 7/14/2017 6:39:45 AM
Mylan (MYL) And BioCon (BIOCON.NS) Present Clinical Data On Insulin Glargine At The American Diabetes Association's 77th Scientific Sessions 6/12/2017 7:00:50 AM
U.S. FDA Accepts Biologics License Application (BLA) For Mylan (MYL) And BioCon (BIOCON.NS)'s Proposed Biosimilar Pegfilgrastim For Review 2/16/2017 7:22:02 AM
Mylan (MYL) Release: FDA Accepts Biologics License Application (BLA) For Pharma And BioCon (BIOCON.NS)'s Proposed Biosimilar Trastuzumab 1/11/2017 6:24:25 AM
JAMA Publishes Mylan (MYL) And BioCon (BIOCON.NS)'s Proposed Biosimilar Trastuzumab Phase 3 Data 12/27/2016 10:57:33 AM
Mylan (MYL) And BioCon (BIOCON.NS) Announce U.S. FDA Submission For Proposed Biosimilar Trastuzumab 11/9/2016 11:40:15 AM
Mylan (MYL) And BioCon (BIOCON.NS) Announce Regulatory Submission For Insulin Glargine Accepted For Review By EMA 11/3/2016 7:37:39 AM
Mylan (MYL) And BioCon (BIOCON.NS) Announce Regulatory Submission For Proposed Biosimilar Trastuzumab Accepted For Review By EMA 8/25/2016 9:39:50 AM
Mylan (MYL) And BioCon (BIOCON.NS) Announce Regulatory Submission For Proposed Biosimilar Pegfilgrastim Accepted For Review By European Medicines Agency 7/21/2016 9:50:41 AM
BioCon (BIOCON.NS), Quark Pharmaceuticals Inc. Announce Initiation Of Pivotal Phase II/III Study Of QPI-1007 In Rare Eye Disease In India 6/23/2016 6:09:02 AM
12345
//-->